Loading
A phase 3 trial of Savolitinib, Osimertinib, Pemetrexed, Cisplatin and Carboplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment is a phase 3 interventional study registered as NCT05261399 by AstraZeneca, with 341 participants enrolled, started 2022-08-03 and due to reach its primary completion in 2026-07-06. Interventions recorded: Savolitinib, Osimertinib, Pemetrexed, Cisplatin and Carboplatin.
Shares Osimertinib, Pemetrexed, AstraZeneca, Cisplatin and the tag pipeline.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin and the tag pipeline.
Shares Savolitinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Osimertinib, EGFR-mutated non-small-cell lung cancer and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin and the tag pipeline.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.